Table 2 FDA-approved targeted and immune therapies for HCC
From: Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview
Generic drug | Brand name | Target | Availability in Egyptian Market |
|---|---|---|---|
Cabozantinib | Cabometyx and Cometriq | Multikinase inhibitor | Available |
Lenvatinib | Lenvima | Multikinase inhibitor | Available |
Sorafenib | Nexavar | Multikinase inhibitor | Available |
Regorafenib | Stivarga, and Regonix | Multikinase inhibitor | Available |
Nivolumab | Opdivo | Immune check point inhibitors | Available |
Pembrolizumab | Keytruda | Immune check point inhibitors | Available |
Ramucirumab | Cyramza | Human monoclonal antibody against vascular endothelial growth factor 2(VEGFR 2) | Available |